|Home | About | Journals | Submit | Contact Us | Français|
Galectin-1 is a major anti-inflammatory protein expressed by the placenta and immune cells that can bias the character of inflammatory responses toward the Th2 type. Galectin-1 is expressed in immune privileged sites, it can facilitate immune tolerance and tumor immune escape, and it has been successfully used for the suppression of experimental autoimmune diseases as well as graft versus host disease in murine models. We propose that an abnormal immune response in some pregnancy complications may be associated with changes in placental expression of galectin-1. To test this hypothesis, we studied placental galectin-1 mRNA and protein expression and localization in women with preeclampsia (PE) and in those who delivered a small-for-gestational age (SGA) neonate.
This cross-sectional study included pregnant women matched for gestational age at delivery in the following groups: 1) severe PE (n=10); 2) severe PE complicated with SGA (n=10); 3) SGA without PE (n=10); and 4) controls (n=10). Galectin-1 mRNA and protein were localized in placentas by in situ hybridization and immunofluorescence microscopy. Galectin-1 mRNA expression was determined by quantitative real-time RT-PCR, and galectin-1 protein content by Western blot. Non-parametric statistics were used for analysis.
1) In normal term placentas, galectin-1 mRNA or immunofluorescence signals were detected in the trophoblasts, villous stromal cells, Hofbauer cells, endothelial cells of the villous blood vessels,,and the villous stroma. 2) Placental galectin-1 mRNA expression was significantly higher in severe PE (with or without SGA) than in controls (1.47 fold, p=0.004; 1.44 fold, p=0.003; respectively] and in SGA (1.68 fold, p=0.001; 1.64 fold, p=0.001; respectively]. 3) Trophoblasts in placentas of patients with severe PE had the most intense galectin-1 immunostaining.
1) We report for the first time the placental expression and localization of galectin-1 mRNA and demonstrate that the protein is abundantly present in third trimester human placentas. 2) Placental galectin-1 expression is higher in severe PE than in normal pregnancy regardless of the presence of SGA. 3) However, it is not altered in SGA without PE. We propose that the increased placental expression of galectin-1 in patients with severe PE may represent a fetal response to an exaggerated systemic maternal inflammation; thus, galectin-1 may be implicated in maternal-fetal immune tolerance in humans.
Preeclampsia (PE) is considered a maternal disease which is associated with fetal growth restriction in 10–25% of the cases, while pregnancies complicated with growth restricted (IUGR) fetuses or small-for-gestational age (SGA) neonates without PE usually have no appreciable clinical impact on the mother[1,2]. These `great obstetrical syndromes' share similar pathophysiologic mechanisms, such as generalized endothelial cell dysfunction[4–8], abnormal placentation[9–16], anti-angiogenic state[17–35], chronic uteroplacental ischemia[36–40], and an increased maternal systemic inflammatory response[41–46]. The latter is highly exaggerated in PE and involves the activation of the innate immune system[42,47–49].
Galectins are cytokine-like immunoregulatory proteins, members of an evolutionarily-conserved protein family that share similar structures, carbohydrate recognition domains (CRDs) and affinity for beta-galactosides present on cell surface glycoconjugates[50–56]. Galectins exhibit preferential binding to a subset of ligands[57–59] and are implicated in deciphering the high-density “glycocode” stored in glycoproteins, proteoglycans and glycolipids[60–62]. Their versatile functions include the regulation of cell-cell/matrix interactions, cell cycle, apoptosis, cell migration, and the recognition of microbial glycosignatures[50,53,55,56]. Galectins can affect both the innate and the adaptive arms of the immune system, inhibiting (e.g. galectin-1)[56,63] or augmenting (e.g. galectin-3) the inflammatory response.
Galectin-1 was the first human galectin discovered, purified and cloned[65,66] from the placenta. Subsequent studies presented the immunolocalization of galectin-1 in normal first and third trimester placentas; however, the described expression patterns lacked consistency[67–71]. Galectin-1 is expressed in immune-privileged sites (e.g. testis and brain)[72,73], and upregulated in tumors (e.g. melanoma), presumably to facilitate the escape of immunosurveillance[63,74]. Galectin-1 has pleiotropic binding activity [57,59,63] and mediates a wide variety of immune cell interactions (Figure 1), mainly promoting immune tolerance and down-regulating the innate and adaptive immune responses. Moreover, galectin-1 has potent anti-inflammatory effects including: 1) inhibition of acute inflammation; 2) suppression of T cell-mediated autoimmune diseases[77–80]; 3) amelioration of graft versus host disease; and 4) biasing the character of the immune response to the Th2 type.
The overexpression of galectin-1 has been observed in cultured human endothelial cells, in the synovia of rheumatoid arthritis patients and in activated immune cells[84–87]. Galectin-1 was proposed to regulate the extent of the immune response during inflammation; thus, it might also be involved in the complex inflammatory responses observed in pregnancy complications.
The aims of this study were to determine the: 1) cellular localization of galectin-1 mRNA and protein in normal third trimester placentas; and 2) changes in placental galectin-1 expression in patients with severe PE with and without SGA, as well as in those patients without PE who delivered an SGA neonate.
This cross-sectional study included pregnant women in the following groups: 1) severe PE (n=10); 2) severe PE with SGA (n=10); 3) SGA without PE (n=10); and 4) pregnant women with preterm and term labor (control group, n=10). Women with severe PE or SGA were matched for gestational age at delivery within two weeks of gestation to women in the control group. Patients with multiple pregnancies, preterm prelabor rupture of membranes, histologic chorioamnionitis, stillbirth or fetal congenital or chromosomal abnormalities were excluded. Samples and data were retrieved from the bank of biological samples and clinical databases of the Perinatology Research Branch. All patients were enrolled at Hutzel Women's Hospital, Detroit, MI, USA, and provided written informed consent prior to the collection of samples. The utilization of samples for research purposes was approved by the Institutional Review Boards of both Wayne State University and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD/NIH/DHHS). Many of these samples have been employed to study the biology of inflammation in normal pregnant women and those with pregnancy complications.
PE was defined as hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg on at least two occasions, 4 hours to 1 week apart) associated with proteinuria (≥300 mg in a 24 hour urine collection, or two dipstick measurements of ≥1+ , or one dipstick measurement of ≥2+). Severe PE was defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg and/or proteinuria greater than 5 g in a 24 hour collection or >3+ on dipstick and in the presence of multi-organ involvement. SGA was defined as neonatal birthweight below the 10th percentile for gestational age at birth according to the national birthweight distribution. Labor was defined by the presence of regular uterine contractions at a frequency of at least 2 contractions every 10 minutes with cervical changes resulting in delivery <37 (preterm) or ≥37 (term) completed weeks of gestation. Control women with preterm or term labor delivered neonates with a birthweight appropriate-for-gestational age (≥10th and ≤90th percentile).
The 123bp fragment of human galectin-1 cDNA generated by PCR (forward primer: CATCTCTCTCgggTggAgTC, reverse primer: gAAggCACTCTCCAggTTTg) was subcloned into pGEM-T Easy vector (Promega Corp., Madison, WI, USA) containing SP6 and T7 polymerase promoters. Digoxigenin-labeled anti-sense and sense riboprobes were generated with SP6 and T7 polymerases after linearization of the plasmid with Bam HI and Hind III, respectively. 5 μm sections of paraffin-embedded villous tissues were deparaffinized, hydrated in xylene and graded ethanol and then treated with proteinase K (15 μg/ml) in 0.1 M Tris buffer (pH 8.0) and 50 mM EDTA for 10 minutes at 37°C. Slides were fixed with 4% paraformaldehyde for 20 minutes and acetic anhydride for 10 minutes. Sections were incubated in a hybridization buffer containing digoxigenin-tagged galectin-1 riboprobe (2 μg/ml). Hybridization was carried out in a humidity chamber overnight at 55°C. After repeated post-hybridization washes, sections were incubated with alkaline phosphatase-conjugated anti-digoxigenin antibody (Roche Diagnostics, Indianapolis, IN) for 1 hour at room temperature. Nitro-blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt were used for detection of the hybridization signal.
Total RNA was isolated from snap-frozen placental villous tissues using TRIzol reagent (Invitrogen Carlsbad, CA, USA) and then Qiagen RNeasy kit (Qiagen, Valencia, CA, USA) according to the manufacturers' recommendations. The 28S/18S ratio and the RNA integrity number (RIN) were assessed using a Bioanalyzer 2100 (Agilent Technologies, Wilmington, DE, USA). An A260nm/A280nm ratio of 1.8, a 28S/18S ratio of 1.3, and a RIN of 6 were minimum requirements for inclusion in expression analysis.
Total RNA was reverse transcribed with a TaqMan Reverse Transcription Reagent kit using random hexamers (Applied Biosystems, Foster City, CA, USA). The standard curve was run with the LGALS1 TaqMan Gene Expression Assay (Hs00169327_m1; Applied Biosystems, Foster City, CA, USA) to determine the quantity of cDNA needed for an approximate cycle threshold (Ct) of 25. The human RPLPO (large ribosomal protein) TaqMan Endogenous Control (part number: 4326314E) was used as the housekeeping gene for relative quantitation. The LGALS1 and RPLPO genes were then run in triplicates for each case to allow for the assessment of technical variability.
Five μm sections of snap-frozen villous tissues were fixed with 4% paraformaldehyde for 1 hour at room temperature and acetone for 1 minute at −20°C. Slides were preincubated with Image-it FX signal enhancer (Molecular Probes, Carlsbad, CA, USA) for 30min and CAS blocking solution (Zymed, San Francisco, CA, USA) for 10 minutes. Sections were incubated with goat anti-human galectin-1 IgG (R&D Systems, Minneapolis, MN, USA) and goat isotype control primary IgG at 1:50 dilutions for 1 hour, and with Alexa Fluor 568 conjugated donkey anti-goat IgG (Invitrogen Co., Carlsbad, CA, USA) at 1:1000 dilution for 1 hour. Sytox Green nuclear counter stain (Cambrex, North Brunswick, NJ, USA) was applied at a 1:100,000 dilution for 3 minutes. Stainings were performed on an autostainer (Dako, Carpinteria, CA, USA). Fluorescent and differential interference contrast (DIC) images were captured with a Zeiss Axiovert 200 Ultra-View ERS Rapid Confocal Imager equipped with an argon laser and a Zeiss Fluar 40x / 1.3 oil objective. Images were evaluated by Perkin Elmer ImageSuite 3.0 version 14 (Perkin Elmer Inc., Waltham, MA, USA).
Placental villous tissues were lysed with RIPA buffer (Sigma, St Louis, MO, USA) containing protease inhibitor (Roche Diagnostics, Mannheim, Germany). Thirty μg of the protein lysates and 15 ng of recombinant human galectin-1 (R&D Systems, Minneapolis, MN, USA) were electrophoresed on 15% (w/v) SDS-polyacrylamide gels and electroblotted onto PVDF membranes (Bio-Rad, Hercules, CA, USA). The membranes were probed with a goat anti-human galectin-1 IgG (R&D Systems, Minneapolis, MN, USA) or with a murine monoclonal anti-β-actin antibody (Sigma, St Louis, MO, USA) at 1:2,000 dilutions for 1 hour; then incubated with horse-radish peroxidase conjugated donkey anti-goat IgG (R&D Systems, Minneapolis, MN, USA) or goat anti-mouse IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) at 1:4,000 dilutions for 1 hour. Protein bands were detected by ECL chemiluminescence (Amersham Biosciences, Piscataway, NJ, USA). The specificity of the anti-human galectin-1 IgG was validated by testing with human recombinant galectins-2,-3,-4,-7, and -8 in the same experimental conditions as galectin-1.
Comparisons among groups were performed using Fisher's exact test for proportions and one-way ANOVA test for normally distributed continuous variables, as well as Kruskal-Wallis test and Mann-Whitney U test for non-normally distributed continuous variables. For the analysis of qRT-PCR data, pair-wise group comparisons were performed using “Generalized estimating equations”. In parallel, the t-test was also applied by averaging over the three technical replicates (Ct values) of each subject. To determine the influence of the gestational age on LGALS1 gene expression within the groups, a linear model was fitted in which the gestational age was used as a predictor for the Ct values. An adjustment of p-values to account for the six different comparisons among the four groups was performed using the Bonferroni method. An adjusted p-value of <0.05 was considered to be statistically significant. The R statistical software (www.r-project.org) including required libraries and SPSS version 12.0 (SPSS Inc., Chicago, IL) were used for the analyses.
Table I displays the demographic and clinical characteristics of the study groups. A larger proportion of women with severe PE complicated by SGA had chronic hypertension than did patients in the other study groups. Placental histopathologic findings consistent with maternal underperfusion[94,95] (e.g. increased syncytial knots, increased intervillous fibrin, distal villous hypoplasia) were more frequent in preterm than in term cases of SGA without PE and in severe PE with or without SGA.
Galectin-1 mRNA in situ hybridization signals were readily detectable in normal term villous placentas, and a similar pattern was observed with galectin-1 immunofluorescence. mRNA hybridization signals were distinct in the trophoblastic layers, especially in cytotrophoblasts, and were also detected in stromal cells (Figure 2A). Immunofluorescence microscopy demonstrated galectin-1 immunopositivity of trophoblasts, Hofbauer cells, stromal cells, and the endothelium of the villous blood vessels (capillaries, arterioles and venules), as well as the syncytiotrophoblast apical membrane and the villous stroma (Figure 2B).
Placental galectin-1 mRNA expression was significantly higher in severe PE (1.44 fold, p=0.003) and severe PE complicated by SGA (1.47 fold, p=0.004) than in gestational age matched controls. In addition, there was a significantly higher placental galectin-1 mRNA expression in severe PE with or without SGA than in SGA without PE (1.68 fold, p=0.001; 1.64 fold, p=0.001; respectively). However, there was no difference in galectin-1 mRNA expression between the SGA and control groups and between patients with severe PE and SGA and those with severe PE alone (Figure 3). In these subsets of patients, gene expressions within the groups did not depend on gestational age.
In control placentas, galectin-1 immunopositivity was detected in trophoblasts, stromal cells, Hofbauer cells, endothelial cells of the villous blood vessels, and the villous stroma (Figure 4A). In patients with SGA without PE, galectin-1 immunofluorescent staining was similar to that in controls (Figure 4B). Severe PE complicated with SGA was characterized by villous galectin-1 immunofluorescence signal present in all cell types, with the strongest signal in trophoblasts, stromal cells and the stroma (Figure 4C). Similarly, in severe PE without SGA, trophoblasts, stromal cells, and stroma had the most intense immunofluorescent staining (Figure 4D). Immunoblots revealed a 15 kDa immunoreactive protein in all placentas, consistent with the size of galectin-1 monomer. Compared to gestational age matched controls, the strongest signal was detected in the severe PE groups both preterm and term as represented in Figure 5. When testing for cross-reactivity on Western blots, the primary antibody specifically recognized placental and recombinant galectin-1 but not recombinant galectins-2,-3,-4,-7 and -8.
1) Galectin-1 mRNA is ubiquitously expressed in the villous placenta, and its expression pattern is similar to that of galectin-1 immunostaining; 2) placental galectin-1 mRNA expression was significantly increased in severe PE with or without SGA compared to gestational age matched controls and to SGA; and 3) increased placental galectin-1 immunofluorescence was detected in trophoblasts, stromal cells and the villous stroma in cases of severe PE with or without SGA when compared to controls or to SGA.
This is the first study that localizes galectin-1 in the villous placenta with mRNA in situ hybridization along with sensitive immunofluorescence staining. The combination of these methods allowed us to identify galectin-1 in all cell types of the villi, as well as in the syncytiotrophoblast apical membrane at the maternal-fetal interface. Other studies localized galectin-1 with immunohistochemistry in first and third trimester normal human placentas[67–71]; however, these reports gave less comprehensive and inconsistent results. Two studies demonstrated galectin-1 immunopositivity of mesenchymal cells in both trimesters[67,69]. The villous stroma, where galectin-1 had been co-localized with fibronectin and laminin, was also immunopositive in the first trimester[67,70] and at term. Endothelial cells, vessel walls[67,68] and the syncytiotrophoblast was shown to be galectin-1 positive in the first and third trimester[68,71]; however, villous cytotrophoblast immunoreactivity was reported only at term. Overall, none of these reports were consistent with others in terms of the described expression patterns[67–71]. This inconsistency might be the consequence of the differences in gestational age of the tissues, the applied methodologies and the type of antibodies used. In our study, the specificity of the immunostaining was supported by the following: 1) there was no immunofluorescent signal (besides the nuclear counterstain) when the isotype control primary antibody was applied; 2) the antibody that recognized placental and recombinant galectin-1 did not cross-react with homologous galectins on Western blot analyses; and 3) in situ hybridization confirmed galectin-1 mRNA expression in immunopositive cells.
Galectin-1 is expressed in placentas of other mammals[97,98]. Murine galectin-1, which has an 88% amino acid sequence identity to its human ortholog, was found to be ubiquitously expressed in the mouse placenta, including trophoblast cells in the labyrinth region and the spongy layer. Recent publications revealed that cytoplasmic galectin-1 can be translocated to the intra-[63,99] and extracellular side of the cell membrane[63,100], and that recombinant galectin-1 is capable of binding to human syncytiotrophoblast and extravillous trophoblast cell surface. Thus, the abundance and ubiquitous expression of galectin-1 by the villous tissues and its presence at the maternal-fetal interface suggests that this galectin might have several functions in the placenta.
The most important biological processes to which galectin-1 has been linked include connective tissue organization, tumor invasiveness and metastasis, regulation of cell proliferation and differentiation, and local immunomodulation. Currently, there are no functional data on the effect of galectin-1 on normal human placental cells. Based on its placental expression pattern and functional effects on other cell types, we propose that galectin-1 may participate in the following processes in the placenta:
The strong galectin-1 immunopositivity of villous stromal cells and the villous stroma found in this study is in accordance with the abundance of galectin-1 in cells of mesenchymal origin and their ECM, where it was proposed to have a pivotal role in the organization and presentation of connective tissue components and tissue development[63,70]. Galectin-1 co-localizes, binds and cross-links beta-integrins and poly-N-acetyl-lactosamine-rich components of the placental ECM (e.g. laminin and fibronectin)[59,69,70,96,102], which are important in the control of cell attachment, migration, invasion, as well as the assembly and remodeling of the ECM. Indeed, overexpression of galectin-1 decreases the incorporation of its ligands (vitronectin and chondroitin sulphate) into the ECM of smooth muscle cells. Based on these findings, we propose that the expression of galectin-1 may have importance in the cross-talk between trophoblasts, stromal cells and the stroma during placentation and in the development and maintenance of villous tissues.
Our data demonstrated that galectin-1 is expressed by the endothelium of villous capillaries, arterioles and veins in the villous placenta. This is consistent with previous studies demonstrating the expression of galectin-1 in endothelial cells of human umbilical vein and aorta, bovine aorta, and microvessels in rat lung and mouse lung and brain[82,104–106]. Microvascular endothelial cells form specialized microcirculatory networks, which regulate coagulation, angiogenesis and the distribution of activated immune cells, thus, innate and adaptive immune responses. Indeed, galectin-1 was demonstrated to inhibit polymorphonuclear cell chemotaxis and trans-endothelial migration in vitro and interleukin (IL)-1-induced polymorphonuclear cell recruitment into the mouse peritoneal cavity in vivo. Galectin-1 inhibited T cell migration across endothelial cells expressing increased amounts of the protein, and induced apoptosis of susceptible T cells bound to cultured human aortic endothelial cells expressing high amounts of galectin-1. These data suggest that galectin-1 expressed by the villous endothelium may also be part of an anti-inflammatory loop, regulating recruitment and transmigration of fetal immune cells in the villi.
Hofbauer cells are also regarded as fetal macrophages capable of phagocytosis[109–111] and production of cytokines [e.g., IL-1, IL-8, suppressor of cytokine signaling (SOCS) proteins][112–114], chemokines [e.g. macrophage inhibitory protein (MIP)-1-beta] and phagocytosis-related enzymes [acid phosphatase (ACP) and glucose-6-phosphate dehydrogenase (G6PD)]. Hofbauer cells exhibiting strong G6PD staining and ACP labeling in the phagosomes are phagocytic cells. The percentage of these activated macrophages is significantly higher in placentas of patients with infectious miscarriages than in gestational age-matched controls. Of interest, there is an up-regulation of galectin-1 expression in macrophages during their activation[84,87] and in infection. In turn, galectin-1 inhibits macrophage microbicidal activity  decreases iNOS expression and NO metabolism, and regulates constitutive and inducible expression of high affinity FcγRI (CD64) and phagocytosis. Based on these data, galectin-1 may also have a role in the fetal response to pathogenic insults and in the regulation of the extent of the inflammatory reasponse in the villi.
This study confirmed the expression of galectin-1 in the syncytiotrophoblast[68,70,71] and showed its sublocalization onto the apical membrane. The syncytiotrophoblast is a rich source of immunomodulatory molecules[118–120], and those with immunosuppressive properties [e.g. human chorionic gonadotropin, human placental lactogen, indoleamine 2,3-dioxygenase, CD95L/Fas ligand, pregnancy-specific beta-1 glycoproteins, SOCS proteins, TNF-related apoptosis-inducing ligand (TRAIL)][114,121–126] are proposed to attenuate maternal immune responses and, thus, maintain tolerance to the fetus. The evidence supporting that placental galectin-1 may also have an important role in immune tolerance includes the following: 1) Galectin-1 reduces host alloreactivity and ameliorates graft versus host disease in mice; 2) it is capable of triggering the apoptosis of immature thymocytes and activated T cells, biasing the immune responses to the Th2 type[63,127,128], and suppressing experimental T cell-mediated autoimmune diseases (e.g. encephalomyelitis, retineal disease, arthritis or hepatitis) in rats and mice[77–80]; 3) galectin-1 plays a role in the immune escape of a wide variety of tumors (e.g. head and neck carcinoma, astrocytoma, glioma, melanoma) by possibly down-regulating tumor resident T cell survival and linking tumor hypoxia and immune privilege [74,129–132]; 4) galectin-1 is up-regulated in mammary adenocarcinoma cells by transforming growth factor (TGF)-β, an important molecule in tolerance; 5) it is highly expressed in uterine NK cells and activated CD4+CD25+ regulatory T cells that have been implicated in maternal-fetal tolerance [125,135,136].
Moreover, a recent study reported that LGALS1-null mice show higher rates of fetal loss compared to wild-type mice in allogeneic matings, and treatment with recombinant galectin-1 prevents fetal loss and restores tolerance through various mechanisms, such as the induction of tolerogenic dendritic cells and the expansion of CD4+CD25+ IL-10 secreting regulatory T cells. Thus, galectin-1 expressed by uterine tissues (decidua, myometrium) has been suggested to have a pivotal role in conferring maternal-fetal tolerance. These results mainly relate the effects of galectin-1 to the maternal side of the fetal-maternal interface. However, based on the abundance of galectin-1 in the placenta, especially in the syncytiotrophoblast, our study suggests that galectin-1 may also be important in the fetal immune response.
A novel finding described herein is that both galectin-1 mRNA expression and immunopositivity were significantly increased in the placentas of patients with severe PE. The up-regulation of galectin-1 in severe PE was independent of gestational age, placental histopathologic findings and the presense or absence of SGA; thus, it is most likely to be associated with the exaggerated maternal systemic inflammatory response[41–46,138], which is generally found in PE but may be less developed in pregnancies complicated by SGA or IUGR. The semi-quntitative results of our immunostainings are in accord with those described by a recent study; however, we also quantitatively verified these results by measuring galectin-1 mRNA expression in the villi.
An anology between PE and allograft rejection has recently been proposed . It was reported that in rejected human kidney allograft, galectin-1 was up-regulated in endothelial cells of peritubular capillaries and large vessels in inflammatory regions, at the sites of direct contact between host immune cells and the rejected graft. In the light of this finding, it is not surprising that we found up-regulation of galectin-1 expression in the syncytiotrophoblast, which is also in direct contact with activated maternal leukocytes. Moreover, galectin-1 is a pattern-recognition molecule which operates as a “cell stress sensor” under physiological and pathological conditions. It is up-regulated during cell activation and at the time and loci of acute and chronic inflammation and infection[82–87], where it is proposed to regulate the extent of the immune responses. “Danger signals” and pattern-recognition receptors at the maternal-fetal interface have recently been proposed to create an abnormal placental cytokine milieu and link the activation of the innate immune system and PE [48,49]. Hence, the increased expression of galectin-1 in trophoblasts of patients with severe PE may reflect an enlarged “cellular stress” response.
Recently, an analogy between immune responses to infections and transplants, which involves terminating mechanisms that may help to avoid damage to either normal or infected tissues, has been proposed . The newly evolved ‘danger model’ of immunity suggests that tissues may have control over immune cells and restrict the class and extent of immune reactions[144, 145]. The current approach in the immunology of pregnancy that has challenged the traditional transplantation paradigm also focuses on the unique uterine immune response to the placenta and on the local interactions between placental and maternal immune cells. The increased expression of galectin-1 in the placenta of patients with severe PE is in agreement with these concepts, and may represent a mechanism by which the placenta may control exaggerated immune responses, which include both the fine-tuning of host-pathogen interactions and the maintenance of maternal-fetal immune tolerance.
We report for the first time the placental expression and localization of galectin-1 mRNA, and demonstrate that the protein is abundantly present in third trimester placentas. Placental galectin-1 expression is higher in severe PE than in normal pregnancy, regardless of the presence of SGA. This finding was not observed in patients with SGA alone. We propose that the increased placental expression of galectin-1 in patients with severe PE may represent a local response to systemic maternal inflammation, suggesting that galectin-1 may be implicated in maternal-fetal tolerance.
The authors thank Dr. Susan Land, Daniel Lott, and Ms. Sarah McNorton at the Applied Genomics Technology Center of Wayne State University for performing the qRT-PCR reactions. We wish to acknowledge the invaluable contributions of Dr. Yu Mi Han, Dr. Sung-Su Kim, Ms. Lorri McLuckie, Ms. Rona Wang, Adam Pitt, Ms. Sandy Field, Ms. Nancy Hauff, Gerardo Rodriguez, and the nursing staff of the Perinatology Research Branch and the Detroit Medical Center to this manuscript.
This research was supported in part by the Intramural Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS.